Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk

Autor: Michel R. Le May, Pietro Di Santo, Chantal Gaudet, Trevor Simard, Jeffrey A. Marbach, Benjamin Hibbert, Joanne Joseph, F. Daniel Ramirez, Juan J Russo, Derek So, Pouya Motazedian, Richard G. Jung, Alisha Labinaz, Michael Froeschl, Steven Promislow, Simon Parlow, Robert Moreland, Aun-Yeong Chong, Paul Boland
Přispěvatelé: Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
030213 general clinical medicine
Adenosine
medicine.medical_treatment
Myocardial Infarction
Coronary Artery Disease
Coronary Angiography
030226 pharmacology & pharmacy
Coronary artery disease
0302 clinical medicine
Medicine
Prospective Studies
Registries
Myocardial infarction
General Pharmacology
Toxicology and Pharmaceutics
General Neuroscience
lcsh:Public aspects of medicine
Hazard ratio
Articles
General Medicine
Middle Aged
3. Good health
Stroke
Cardiology
Biomarker (medicine)
Female
medicine.drug
medicine.medical_specialty
Acute coronary syndrome
Revascularization
Risk Assessment
Article
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
Percutaneous Coronary Intervention
Internal medicine
Humans
Aged
business.industry
Research
lcsh:RM1-950
lcsh:RA1-1270
medicine.disease
lcsh:Therapeutics. Pharmacology
Heart Disease Risk Factors
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
Biomarkers
Mace
Follow-Up Studies
Zdroj: Clinical and Translational Science, Vol 14, Iss 1, Pp 354-361 (2021)
Clinical and Translational Science.
Clinical and Translational Science., Wiley, 2020, ⟨10.1111/cts.12886⟩
Clinical and Translational Science
ISSN: 1752-8054
1752-8062
Popis: Adenosine boasts promising preclinical and clinical data supporting a vital role in modulating vascular homeostasis. Its widespread use as a diagnostic and therapeutic agent have been limited by its short half-life and complex biology, though adenosine-modulators have shown promise in improving vascular healing. Moreover, circulating adenosine has shown promise in predicting cardiovascular (CV) events. We sought to delineate whether circulating plasma adenosine levels predict CV events in patients undergoing invasive assessment for coronary artery disease. Patients undergoing invasive angiography had clinical data prospectively recorded in the Cardiovascular and Percutaneous ClInical TriALs (CAPITAL) revascularization registry and blood samples collected in the CAPITAL Biobank from which adenosine levels were quantified. Tertile-based analysis was used to assess prediction of major adverse cardiovascular events (MACE; composite of death, myocardial infarction, unplanned revascularization, and cerebrovascular accident). Secondary analyses included MACE subgroups, clinical subgroups and adenosine levels. There were 1,815 patients undergoing angiography who had blood collected with adenosine quantified in 1,323. Of those quantified, 51.0% were revascularized and 7.3% experienced MACE in 12 months of follow-up. Tertile-based analysis failed to demonstrate any stratification of MACE rates (log rank, P = 0.83), when comparing low-to-middle (hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.68-1.78, P = 0.70) or low-to-high adenosine tertiles (HR 0.95, 95% CI 0.56-1.57, P = 0.84). In adjusted analysis, adenosine similarly failed to predict MACE. Finally, adenosine did not predict outcomes in patients with acute coronary syndrome nor in those revascularized or treated medically. Plasma adenosine levels do not predict subsequent CV outcomes or aid in patient risk stratification.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje